Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition risk. Read why RVMD stock is a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results